Skip to main content

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

IASLC 20th World Conference on Lung Cancer: Independent satellite symposium

Simplifying the sequencing of treatment in NSCLC with no actionable mutations

Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn

This independent symposium, led by an expert international faculty, discussed treatment choices for non-small-cell lung cancer (NSCLC) without targetable mutations, surveying current standards in care against the latest clinical trial data.

Scientific summary

Watch the video take-home messages from the faculty below.

Learning objectives

The aim of the symposium was to enable participants to:

  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
  • Explain how to identify hyperprogressive disease and its influence on treatment decisions

Enriched treatment pathway

Follow the link below to sign up for updates on this upcoming practical tool, which will take users through the different stages of NSCLC whilst providing region-specific incidence statistics, linked articles, clinical trials, article summaries, and recorded interviews with experts.

Enriched treatment pathway


Our experts present their take-home messages from the symposium:

Corey Langer

Read Dr Langer's full bio here

Enriqueta Felip

Read Dr Felip's full bio here

David Heigener

Read Dr Heigener's full bio here

Myung-Ju Ahn

Read Dr Ahn's full bio here


This symposium has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Target audience

The symposium and enduring materials are targeted at international (medical and radiation) oncologists and any other healthcare professionals involved in the diagnosis, treatment and follow-up of patients with lung cancer.

Educational grant

This program was made possible thanks to an independent educational grant from Eli Lilly and Company.

Contact us

Springer Healthcare IME.

Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK